Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4947 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 19 20 21 ... 48 49 50  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Lundbeck–LeadXPro: drug discovery services, 201910– collab structural proteomics services using X-ray + cryo-EM for small molecule drug discovery 2019-10-07
Rentschler–Sumitomo: biologics contract manufacturing, 201910– collab expansion SPI supports marketing + delivery of Rentschler CDMO services in Japan 2019-10-04
Aeovian Pharmaceuticals–Apollo Health Ventures: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Apollo HV 2019-10-03
Aeovian Pharmaceuticals–Evotec: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Evotec 2019-10-03
Aeovian Pharmaceuticals–SEVERAL: investment, 201910 financing round Series A $37m led by VenBio + Sofinnova Investments 2019-10-03
Aeovian Pharmaceuticals–Sofinnova: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor Sofinnova Investments 2019-10-03
Aeovian Pharmaceuticals–VenBio: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor VenBio Partners 2019-10-03
Freiberg Instruments–Bruker: investment, 201910 acquisition €na of Magnettech EPR business by Bruker 2019-10-02
Cellectis–Lonza: cell therapy contract manufacturing, 201910– supply UCART cell therapy candidates by Lonza in Geleen (NL) 2019-10-01
Eisai–Numab: antibody cancer drug, 201910– collab + license option ww excl developing multi-specific Abs using MATCH platform 2019-10-01
Novartis–Microsoft: artificial intelligence, 201910– collab strategic multiyear AI for drug RnD + commercialisation 2019-10-01
Creoptix–SEVERAL: investment, 201909 financing round Series 1st closing CHF8m incl investors Swisscanto Invest + Waters 2019-09-30
Creoptix–Waters: investment, 201909 financing round Series 1st closing totalling CHF8m incl existing + co-investor Waters Corp 2019-09-30
Creoptix–Zürcher Kantonalbank: investment, 201909 financing round Series 1st closing totalling CHF8m incl new + lead investor Swisscanto Invest 2019-09-30
STipe Therapeutics–SEVERAL: investment, 201909 financing round Series A €20m co-led by Arix Bioscience + Novo Holdings 2019-09-30
Roper Technologies–AMETEK: investment, 201909– acquisition $925m in cash of Gatan Inc from Roper Technologies by AMETEK 2019-09-27
T3 Pharmaceuticals–Boehringer: investment, 201909 2nd financing round totalling CHF12m incl new investor BIVF 2019-09-26
T3 Pharmaceuticals–Reference Capital: investment, 201909 2nd financing round totalling CHF12m incl new investor Reference Capital SA 2019-09-26
T3 Pharmaceuticals–SEVERAL: investment, 201909 2nd financing round CHF12m incl new investors BIVF + Reference Capital SA 2019-09-26
Tacalyx–Boehringer: investment, 201909 seed financing round totalling €7m incl co-lead investor BIVF 2019-09-25
Tacalyx–Creathor Ventures: investment, 201909 seed financing round totalling €7m incl co-investor Creathor Ventures 2019-09-25
Tacalyx–Eurazeo: investment, 201909 seed financing round totalling €7m incl co-investor Idinvest Partners 2019-09-25
Tacalyx–Germany (govt): investment, 201909 seed financing round totalling €7m incl co-investor Coparion 2019-09-25
Tacalyx–High-Tech Gründerfonds: investment, 201909 seed financing round totalling €7m incl co-investor HTGF 2019-09-25
Tacalyx–Huntsworth: public relations, 201909 service existent by Citigate Dewe Rogerson 2019-09-25
Tacalyx–Kurma: investment, 201909 seed financing round totalling €7m incl co-lead investor Kurma Partners 2019-09-25
Tacalyx–Max Planck: antibody discovery technology, 201909c license to plaQorm technology of MPI of Colloids + Interfaces from Max Planck Innovation 2019-09-25
Tacalyx–SEVERAL: investment, 201909 seed financing round €7m co-led by BIVF + Kurma Partners 2019-09-25
Addex–SEVERAL: investment, 201909– filing of Nadaq lisiting of ADSs (without proposing to register any new issuance of secutiries) 2019-09-24
Takeda–Evotec: drug discovery services, 201909– collab strategic multi-year across multiple indications 2019-09-24
AC Immune–LaVoieHealthScience: public relations, 201909– supply service existent US media relations by LHS 2019-09-20
AC Immune–LifeSci: public relations, 201909 supply service existent European investor + media relations by LifeSci Advisors 2019-09-20
Boehringer–Inflammasome: drug delivery technology, 201909– co-developm + license up to 3 retinal disease therapies using IVT drug delivery 2019-09-20
Bruker–Murdoch Univ: analytical technologies, 201909– collab strategic alliance with ANPC incl MS + NMR for phenomics research 2019-09-20
Murdoch Univ–Bruker: NMR spectrometer, 201909 supply NMR FoodScreener 2019-09-20
Oncimmune–IPF Partners: credit, 201909– 202309 credit facility €8.5m four year incl warrant for 2m new ordinary shares IPF Management SA 2019-09-20
Novigenix–BioLizard: bioinformatics, 201909– collab developm of AI-based bioinformatics algorithm to support developm of tests for LITOseek platform 2019-09-19
Themis Bioscience–Farallon Capital: investment, 201909 financing round Series D totalling €40m incl new + co-lead investor Farallon Capital 2019-09-18
Themis Bioscience–Hadean Ventures: investment, 201909 financing round Series D totalling €40m incl new + co-lead investor Hadean Ventures 2019-09-18
Themis Bioscience–SEVERAL: investment, 201909 financing round Series D €40m co-led by Farallon Capital + Hadean Ventures 2019-09-18
Versantis–SEVERAL: investment, 201909 financing round Series B CHF16m led by Swisscanto Invest by ZKB 2019-09-18
Bayer–Informed Data Systems: digital health, 201909– collab + licensing agreem $10m developm + commercialisaing of One Drop technology platform 2019-09-17
Informed Data Systems–Bayer: investment, 201909 Series B financing incl $20m from Bayer 2019-09-17
Life Healthcare Group–AC Immune: PET tracer, 201909 collab existent developm Tau PET tracer PI-2620 with Life Molecular Imaging 2019-09-17
Versantis–Halsin Partners: public relations, 201909 service existent by Halsin Partners 2019-09-17
Belyntic–Berlin (govt): investment, 201909 seed financing round totalling €1.3m incl lead investor IBB 2019-09-16
Belyntic–High-Tech Gründerfonds: investment, 201909 seed financing round totalling €1.3m incl co-investor HTGF 2019-09-16
Belyntic–PERSON: investment, 201909 seed financing round totalling €1.3m incl co-investor business angel Till Knorr 2019-09-16
Belyntic–SEVERAL: investment, 201909 seed financing round €1.3m led by IBB + incl HTGF + business angel Till Knorr 2019-09-16
GenomSys–Club degli Investitori: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Club degli Investitori 2019-09-16
GenomSys–Dolby Family Ventures: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Dolby Family Ventures 2019-09-16
GenomSys–Elysia Capital: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Elysia Capital 2019-09-16
GenomSys–Preon Capital: investment, 201909 financing round Series A totalling CHF9.3m incl lead investor Preon Capital 2019-09-16
GenomSys–Pygar: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Pygar family office 2019-09-16
GenomSys–SEVERAL: investment, 201909 financing round Series A CHF9.3m led by Preon Capital 2019-09-16
GenomSys–Susman Ventures: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Susman Ventures 2019-09-16
OTHER–Curetis: molecular diagnostics, 201909– collab RnD + option for NGS-based antibiotic resistance testing of Ares Genetics with global IVD firm 2019-09-16
Inotrem–SEVERAL: investment, 201909 financing round Series B €39m led by Morningside Ventures 2019-09-12
Khanu Management–Austria (govt): investment, 201909 1st closing totalling €60m of KHAN Technology Transfer Fund I incl aws 2019-09-12
Khanu Management–EU (govt): investment, 201909 1st closing totalling €60m of KHAN Technology Transfer Fund I incl European Investment Fund 2019-09-12
Khanu Management–Max Planck: investment, 201909 1st closing totalling €60m of KHAN Technology Transfer Fund I incl Max Planck Foundation 2019-09-12
Khanu Management–SEVERAL: investment, 201909 1st closing €60m of KHAN Technology Transfer Fund I 2019-09-12
Orion Corp–Genedata: bioinformatics, 201909– supply license to Genedata Biologics as SaaS for large-molecule RnD to Orion Pharma 2019-09-11
Bayer–Minapharm: GlymaxX technology, 201909– license for use in cell line developm for cancer antibody candidate of Bayer 2019-09-10
Grünenthal–Mesoblast: cell therapy, 201909– strategic collab $15m upfront developm + commercialisation of MPC-06-ID in Europe + Lation America 2019-09-10
BioNTech–SEVERAL: investment, 201909–201910 US IPO $150m+$22.5m with 10m+1.5mADSs at $15/ADS at Nasdaq Global Select Market 2019-09-09
ADC Therapeutics–SEVERAL: investment, 201909–201910 IPO up to approx $230m at NYSE WITHDRAWN 10/19 2019-09-06
iStar Medical–SEVERAL: investment, 201905 financing round Series C €40m led by LSP + Gimv 2019-09-05
PathoQuest–SEVERAL: investment, 201909 financing round €7.57m incl venture loan from Norgine Ventures 2019-09-05
Roche–Abionic: in vitro diagnostics, 201909– collab developm + supply abioSCOPE IVD PoC asthma test panel for asthma management in US for Genentech 2019-09-05
BioNTech–Gates Foundation: investment, 201909 equity investment $55m in connection with anti-infectives collaboration 2019-09-04
Boehringer–Lupin: MEK inhibitor, 201909– license $20m upfront + $700m milestones + royalties to LNP3794 for combi with KRAS inhibitors for cancer 2019-09-04
Curetis–OpGen: investment, 201909– reverse merger with Curetis shareholders holding 72.5% of combined entity 2019-09-04
Gates Foundation–BioNTech: anti-infectives, 201909– collab developm of HIV + TB immunotherapies with up to $100m funding incl equity investment $55m 2019-09-04
FU Berlin–Agilent: mass spectrometer, 201909 supply existent LC/MS/MS + GC/MS systems at FU Berlin used in doping control study with Agilent support 2019-09-03
Grünenthal–Univ Queensland: pain drugs, 201909– collab develop therapies derived from group of alpha-conotoxins for chronic neuropathic pain 2019-09-03
Univ College London–Bruker: atomic force microscope, 201908 supply existent London Centre for Nanotechnology long-term user of NanoWizard systems 2019-09-02
Biocrates–MIG Founds: investment, 201909c financing round incl MIG Fonds + GAF + Austria family office consolidation shareholder structure 2019-09-01
Biocrates–SEVERAL: investment, 201909c financing round incl MIG Fonds + GAF + Austria family office consolidation shareholder structure 2019-09-01
Biocrates–Xolaris Service KVG: investment, 201909c financing round incl MIG Fonds + GAF + Austria family office consolidation shareholder structure 2019-09-01
Celgene–Immatics: cell therapy, 201908– strategic collab + excl option $75m upfront + $1.5b milestones + royalties for three TCR-T targets 2019-08-28
Spitality–Berlin (govt): investment, 201908 seed financing round from Capacura GmbH + VC Fonds Technologie Berlin 2019-08-27
Spitality–Capacura: investment, 201908 seed financing round from Capacura GmbH + VC Fonds Technologie Berlin 2019-08-27
Spitality–SEVERAL: investment, 201908 seed financing round from Capacura GmbH + VC Fonds Technologie Berlin to advance Krankenhaus.de 2019-08-27
ADC Therapeutics–Freenome: pharmacodiagnostics, 201908– collab developm multiomics biomarker for ADCT-402 treatment in DLBCL 2019-08-26
Univ Florence–Bruker: NMR spectrometer, 201908– supply expected first customer for new 1.2 GHz NMR spectrometer 2019-08-26
Merck (US)–Themis Bioscience: vaccine technology, 201908– collab research + license for use of MV technology platform for vaccine development 2019-08-22
Themis Bioscience–Merck (US): investment, 201908 equity investment €na by MSD as part of vaccine collaboration 2019-08-22
Oncorus–SEVERAL: investment, 201908 financing round Series B $79.5m co-led by Cowen Healthcare Investments + Perceptive Advisors 2019-08-21
Araris Biotech–Redalpine: investment, 201908 seed financing round totalling CHF2.5m incl investor Redalpine 2019-08-20
Araris Biotech–Schroders: investment, 201908 seed financing round totalling CHF2.5m incl investor Schroder Adveq 2019-08-20
Araris Biotech–SEVERAL: investment, 201908 seed financing round CHF2.5m with Redalpine + Schroder Adveq + VI Partners 2019-08-20
Araris Biotech–VI Partners: investment, 201908 seed financing round totalling CHF2.5m incl investor VI Partners 2019-08-20
Bayer–Elanco: investment, 201908– acquisition of Bayer Animal Health business for $5.3b in cash + $2.3b in shares 2019-08-20
Boehringer–Univ Texas: cancer drugs, 201908– collab new virtual RnD center to advance new cancer therapies incl KRAS inhibitors + TRAILR2 agonists 2019-08-12
Curetis–HC Wainwright: investment banking, 201908– supply service Curetis retains HC Wainwright to evaluate all strategic options 2019-08-12
LemnaTec–Nynomic: investment, 201908 acquisition €na of assets of bankrupt LemnaTec Gmbh by Nynomic AG 2019-08-12
Biognosys–SEVERAL: investment, 201908 financing round Series G from existing + new institutional + private investors 2019-08-08
BlueRock Therapeutics–Bayer: investment, 201808– acquisition 100% by acquiring remaining 59.2% for $240m upfront + $360m milestones 2019-08-08
a:head bio–red-stars.com data: investment, 201908– milestone-dependent 7-digit EUR seed investment by red-stars.com data AG in a:head bio AG 2019-08-07
next pagenext page 1 2 3 ... 19 20 21 ... 48 49 50  next pagenext page



Advertisement

Picture [iito] No Content Marketing 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px

» top